Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSET
2022-501072-25-02Phase 2Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ischemic stroke comparing Semaglutide + standard of care with Standard of care (2 arms). Planned start Oct 2022; status: authorised.
02
Drugs
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2022-501072-25-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501072-25-02.